Of note, further explorations are required to focus on the novel biomarkers, including the CD8+ tumor infiltrating lymphocytes (TILs) (13), polymerase epsilon (POLE) variation (14), and DNA methylation (15, 16). This evidence concerns the gene POLE and neoplasm.